4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
9.77
+0.11 (1.14%)
At close: Apr 15, 2026, 4:00 PM EDT
9.77
0.00 (0.00%)
After-hours: Apr 15, 2026, 4:10 PM EDT
4D Molecular Therapeutics Employees
4D Molecular Therapeutics had 196 employees as of December 31, 2025. The number of employees decreased by 31 or -13.66% compared to the previous year.
Employees
196
Change (1Y)
-31
Growth (1Y)
-13.66%
Revenue / Employee
$434,740
Profits / Employee
-$714,842
Market Cap
498.77M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 196 | -31 | -13.66% |
| Dec 31, 2024 | 227 | 80 | 54.42% |
| Jun 30, 2024 | 201 | 64 | 46.72% |
| Mar 31, 2024 | 171 | 34 | 24.82% |
| Dec 31, 2023 | 147 | 7 | 5.00% |
| Sep 30, 2023 | 144 | 4 | 2.86% |
| Jun 30, 2023 | 137 | -1 | -0.72% |
| Mar 31, 2023 | 137 | 0 | - |
| Dec 31, 2022 | 140 | 16 | 12.90% |
| Sep 30, 2022 | 140 | 19 | 15.70% |
| Jun 30, 2022 | 138 | 34 | 32.69% |
| Mar 31, 2022 | 137 | 49 | 55.68% |
| Dec 31, 2021 | 124 | 41 | 49.40% |
| Sep 30, 2021 | 121 | 43 | 55.13% |
| Jun 30, 2021 | 104 | 26 | 33.33% |
| Mar 31, 2021 | 88 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 371 |
| ADC Therapeutics | 193 |
| Entrada Therapeutics | 152 |
| Absci | 140 |
| Sutro Biopharma | 137 |
| enGene Therapeutics | 82 |
| Larimar Therapeutics | 71 |
| Lexeo Therapeutics | 59 |
FDMT News
- 4 weeks ago - 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewsWire
- 4 weeks ago - 4DMT to Participate in Upcoming Investor Meetings - GlobeNewsWire
- 7 weeks ago - 4DMT to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - 4DMT Announces New Employment Inducement Grants - GlobeNewsWire
- 2 months ago - 4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD - GlobeNewsWire
- 3 months ago - 4DMT Provides Company Update and Anticipated Development Milestones for 2026 - GlobeNewsWire
- 4 months ago - 4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease - GlobeNewsWire
- 4 months ago - 4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire